Plain-English translation of NCT05100862 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing , a newer cancer medication, combined with antibody therapies to treat two types of lymphoma (follicular and marginal zone) that have come back or stopped responding to previous treatment. Participants will be randomly assigned to receive either this new treatment combination or a standard combination of and . The goal is to see whether the new approach helps people with these difficult-to-treat lymphomas live longer and stay in remission.
Many patients with follicular and marginal zone lymphoma eventually stop responding to standard treatments, and doctors need better options. This medication was designed to work differently than older treatments, and early results suggest it may be more effective—this trial is testing that promise in a large group of patients.
You will receive one of two medication combinations—either the newer treatment or the standard treatment—given by your cancer doctors at a hospital or clinic. You will likely visit the clinic regularly for infusions or to pick up pills and have blood work done. After the initial combination phase, some participants continue taking one medication alone until their disease progresses or they experience side effects. The study will continue until the company has enough information to know whether the newer treatment works better.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
United States